1573025-02-1

Basic information

• Product Name: 3-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-N-(2-morpholinoethyl)-5-(trifluoromethoxy)benzamide
• Synonyms: 3-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-N-(2-morpholinoethyl)-5-(trifluoromethoxy)benzamide
• CAS NO: 1573025-02-1
• Molecular Weight: 833.87
• Mol File: 1573025-02-1.mol

Chemical Properties

• CAS DataBase Reference: 3-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-N-(2-morpholinoethyl)-5-(trifluoromethoxy)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-N-(2-morpholinoethyl)-5-(trifluoromethoxy)benzamide(1573025-02-1)
• EPA Substance Registry System: 3-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-N-(2-morpholinoethyl)-5-(trifluoromethoxy)benzamide(1573025-02-1)

Safety Data

• Hazardous Substances Data: 1573025-02-1(Hazardous Substances Data)

Upstream product

• 453565-90-7 3-bromo-5-(trifluoromethoxy)benzoic acid 
• 1163141-31-8 3-amino-5-(trifluoromethoxy)benzoic acid 
• 1573025-19-0 phenyl (4-((2-chloropyrimidin-4-yl)oxy)naphthalen-1-yl)carbamate 
• 1573025-18-9 3-(2-methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazol-5-amine 
• 95924-34-8 2,2-dimethyl-3-butynoic acid methyl ester 
• 95924-35-9 4,4-dimethyl-3-oxohex-5-ynenitrile 
• 476011-71-9 4-(2-chloro-pyrimidin-4-yloxy)-naphthalen-1-ylamine 
• 1573025-67-8 3-amino-N-(2-morpholinoethyl)-5-(trifluoromethoxy)benzamide 
• 1573025-21-4 1-(4-((2-chloropyrimidin-4-yl)oxy)naphthalen-1-yl)-3-(3-(2-methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)urea 

Relevant articles and documents

KINASE INHIBITORS

There are provided compounds of formula (I), (Formula (I)) wherein R1 to R5, X1, X2, Ar, L, E, A, A1, G and G1 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.